Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.

Published

Journal Article

Veno-occlusive disease continues to be a significant cause of morbidity and early mortality following bone marrow transplantation. This study retrospectively analyzes the incidence and risk factors for severe VOD in 350 patients treated with 4 days of busulfan (total 16 mg/kg) and 2 days of cyclophosphamide (120 mg/kg) at four marrow transplant centers. Using the criteria defined by McDonald et al (Hepatology 1984; 4: 116-122), 93/350 (27%) developed VOD (11% mild, 5% moderate and 11% severe). Multivariate analysis revealed the following risk factors to be significantly associated with severe VOD: pretransplant transaminase and alkaline phosphatase elevation, ciprofloxacin antibiotic prophylaxis, use of estrogen/progestins or vancomycin during the peritransplant period and methotrexate for GVHD prophylaxis. Mild to moderate grades of VOD were not associated with significantly increased mortality but mortality was higher in patients with severe VOD (31%, P = 0.0013). These data suggest that risk factors for VOD may depend on the preparative regimen used and suggest that use of these risk factors may identify a subgroup of patients that can be targetted for studies of prevention of VOD.

Full Text

Duke Authors

Cited Authors

  • Styler, MJ; Crilley, P; Biggs, J; Moul, J; Copelan, E; Topolsky, D; Avalos, B; Penza, S; Sabol, P; Downs, K; Szer, J; Brodsky, I; Marks, DI

Published Date

  • July 1996

Published In

Volume / Issue

  • 18 / 1

Start / End Page

  • 171 - 176

PubMed ID

  • 8832011

Pubmed Central ID

  • 8832011

International Standard Serial Number (ISSN)

  • 0268-3369

Language

  • eng

Conference Location

  • England